Survival

All-Cause Mortality Improved by Advances in Radiotherapy for Hodgkin Lymphoma

All-Cause Mortality Improved by Advances in Radiotherapy for Hodgkin Lymphoma

By

Investigators assessed the impact of advances over time in the treatment of Hodgkin lymphoma on all-cause mortality in patients with Hodgkin lymphoma who received radiotherapy alone or with chemotherapy.

Dapsone, Danazol, Hydroxychloroquine Are Potential Second-line Options in ITP

Dapsone, Danazol, Hydroxychloroquine Are Potential Second-line Options in ITP

By

A retrospective analysis of 28 studies determined that overall response rates for patients with ITP were similar treated with hydroxychloroquine, danazol, or dapsone in the second-line setting were similar.

Radiation Prior to Chemotherapy Prolongs Progression-Free Survival in NSCLC

Radiation Prior to Chemotherapy Prolongs Progression-Free Survival in NSCLC

By

Researchers present findings of a phase 2 study that compared PFS when SBRT is administered prior to maintenance chemotherapy in patients with limited metastatic NSCLC vs chemotherapy alone. Data was presented at ASTRO 59th Annual Meeting.

Severe Mental Illness May Worsen Breast Cancer Survival Outcomes

Severe Mental Illness May Worsen Breast Cancer Survival Outcomes

By

Retrospective analysis of data from more than 19,000 women revealed that all-cause mortality rates are higher in women with breast cancer who have a prior diagnosis of a mental illness.

Overall Survival in Advanced Melanoma Improved With Nivolumab, Ipilimumab Combination

Overall Survival in Advanced Melanoma Improved With Nivolumab, Ipilimumab Combination

By

Overall survival was significantly prolonged in patients with advanced melanoma who were treated with nivolumab plus ipilimumab compared with either drug alone, according to results from the Checkmate 067 study.

Progression-Free Survival in CLL Prolonged With Maintenance Lenalidomide

Progression-Free Survival in CLL Prolonged With Maintenance Lenalidomide

By

Lenalidomide reduced the relative risk of disease progression in a clinical trial of patients with chronic lymphocytic leukemia who did not achieve MRD negative disease state after first-line chemoimmunotherapy.

Progression-Free, Overall Survival in Liposarcoma Improved With Eribulin vs Dacarbazine

Progression-Free, Overall Survival in Liposarcoma Improved With Eribulin vs Dacarbazine

By

Comparison study shows significantly improved overall survival and progression-free survival in patients with advanced LPS treated with eribulin vs dacarbazine.

Reduced-Dose Sorafenib Effective and Economical in Hepatocellular Carcinoma

Reduced-Dose Sorafenib Effective and Economical in Hepatocellular Carcinoma

By

Reducing the initial dose of sorafenib was shown to have some benefits — such as reduced pill burden, lower costs, and decreased AE-related discontinuation rates — and OS was noninferior compared with the standard dose in patients with hepatocellular carcinoma.

Carfilzomib Improves Overall Survival in Relapsed/Refractory Multiple Myeloma

Carfilzomib Improves Overall Survival in Relapsed/Refractory Multiple Myeloma

By

The first interim analysis of the ENDEAVOR trial reported superiority of carfilzomib in some outcomes; however, data on overall survival were not available. This second interim analysis reports on overall survival with carfilzomib for patients with relapsed/refractory multiple myeloma.

Hospital Volume, Quality Impact Survival in Ovarian Cancer

Hospital Volume, Quality Impact Survival in Ovarian Cancer

Survival rate were worse for lower volume hospitals with higher quality scores, versus higher volume hospitals.

Decitabine Improves Overall Survival, Overall Response Rate in Chronic Myelomonocytic Leukemia

Decitabine Improves Overall Survival, Overall Response Rate in Chronic Myelomonocytic Leukemia

By

Patients with high-risk chronic myelomonocytic leukemia (CMML), a MDS/myeloproliferative neoplasm, may experience prolonged overall survival and increased overall response rate from treatment with decitabine.

Survival Predictions for NSCLC Accurate With the Lung Cancer Prognostic Index

Survival Predictions for NSCLC Accurate With the Lung Cancer Prognostic Index

By

The Lung Cancer Prognostic Index (LCPI) provides additional relevant prognostic data for patients with NSCL and may lead to better outcomes.

Rare Case of Langerhans Cell Histiocytosis With Prior ITP Highlights Diagnostic Challenge for Clinicians

Rare Case of Langerhans Cell Histiocytosis With Prior ITP Highlights Diagnostic Challenge for Clinicians

By

A rare case of Langerhans cell histiocytosis (LCH) in a patient with idiopathic thrombocytopenic purpura (ITP) highlights the difficulty in diagnosing LCH.

Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery

Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery

By

Two recent studies examined the benefits of using a 3D bioabsorbable marker to indicate the tumor bed in women with breast cancer who underwent breast conserving surgery (BCS).

Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics

Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics

By

An analysis of rates at certain milestones in clinical trials of treatments for mNSCLC suggests these rates reflect end point results for immunotherapies vs targeted and conventional therapies.

Lenvatinib Improves OS, PFS in Radioiodine-Refractory Differentiated Thyroid Cancer in All Older Patients

Lenvatinib Improves OS, PFS in Radioiodine-Refractory Differentiated Thyroid Cancer in All Older Patients

By

Results from a sub-analysis of the impact of age on the safety and efficacy of lenvatinib in patients with RR-DTC in the SELECT trial showed that lenvatinib significantly increased PFS.

Use of Aspirin, NSAIDs Correlates with Improved Overall Survival in Colorectal Cancer

Use of Aspirin, NSAIDs Correlates with Improved Overall Survival in Colorectal Cancer

By

Regular use of NSAIDs after diagnosis of colorectal cancer correlated with improved survival in survivors with KRAS wild-type tumors.

Clinical Trials May Benefit Oncology Patients

Clinical Trials May Benefit Oncology Patients

By

Research on the effects of research demonstrated that oncology-related clinical trials provide measurable benefits in terms

Survival Increased With First-Line Abiraterone-ADT Combination for Hormone-Naïve Prostate Cancer

Survival Increased With First-Line Abiraterone-ADT Combination for Hormone-Naïve Prostate Cancer

By

Addition of abiraterone to androgen deprivation therapy for patients with hormone-naïve advanced prostate cancer may be a new standard of care.

Vaccine for Cervical Cancer Could Extend Survival in Relapsed Disease

Vaccine for Cervical Cancer Could Extend Survival in Relapsed Disease

Axalimogene filolisbac, an intravenous vaccine currently in clinical trials, could prevent often-fatal cervical cancer relapse.

Combination Therapy Plus Stem-Cell Tx Ups PFS in Multiple Myeloma

Combination Therapy Plus Stem-Cell Tx Ups PFS in Multiple Myeloma

Patients with myeloma that underwent transplantation in addition to RVD had significantly longer median progression-free survival compared to the group that received RVD alone.

Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab

Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab

By

A significantly higher 5-year survival rate was seen in a small subset of patients with NSCLC treated with nivolumab.

Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk

Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk

By

Whole genome sequencing of more than 3000 survivors of childhood cancers demonstrates the value of genetic testing for potential second cancers in this population.

Continuing Nivolumab After Progression of Head and Neck Cancer May Improve Survival

Continuing Nivolumab After Progression of Head and Neck Cancer May Improve Survival

By

Continuing immunotherapy after disease progression extends survival for some patients with head and neck cancer.

Annual Report Shows Decline in Cancer Death Rates, 1975-2014

Annual Report Shows Decline in Cancer Death Rates, 1975-2014

By

The joint report states that overall cancer rates have decreased for men, women, and children in all major race and ethnic groups. However, progress has been limited for some cancers.

Pembrolizumab May Help Combat Mesothelioma

Pembrolizumab May Help Combat Mesothelioma

By

Checkpoint inhibitor pembrolizumab appears well-tolerated with antitumor activity in patients with malignant pleural mesothelioma.

SWOG Study Shows Robust, Longer Survival With Imatinib Therapy for GIST

SWOG Study Shows Robust, Longer Survival With Imatinib Therapy for GIST

By

A phase 3 analysis of SWOG Intergroup Trial S0033 reveals that imatinib significantly extends survival in patients with GIST.

HMT Improves PFS in Serous Carcinoma of the Ovary, Peritoneum

HMT Improves PFS in Serous Carcinoma of the Ovary, Peritoneum

By

Individuals with serious carcinoma of the ovary or peritoneum experienced improved progression-free survival after hormone maintenance therapy.

SCLC: No Benefit from Pravastatin When Added to First-line Chemo

SCLC: No Benefit from Pravastatin When Added to First-line Chemo

By

The addition of pravastatin to first-line chemotherapy did not improve overall survival or progression-free survival in patients with small-cell lung cancer.

1 Year of Adjuvant Trastuzumab Improves Long-Term DFS in Early Breast Cancer

1 Year of Adjuvant Trastuzumab Improves Long-Term DFS in Early Breast Cancer

By

Adjuvant trastuzumab following chemotherapy significantly improves long-term disease-free survival in women with HER2-positive early breast cancer, according to study data.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs